CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Registration Number
- NCT05014724
- Lead Sponsor
- UCB Biopharma SRL
- Brief Summary
This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patient who has taken part in the CIDP04 (NCT04051944) study
- Patient who derives continued benefit from treatment
- All required safety information has been reported as per local laws/regulations, reported to Bionical, as appropriate, and documented in the patient's medical records
- Patient is not pregnant
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method